Obstructive hydrocephalus as complication of a giant nonfunctioning pituitary adenoma: Therapeutical approach

Acta Clinica Belgica

Volumn 53, Issue 1, 1998, Pages 47-52

  Verhelst, J ^a   Berwaerts, J ^a   Abs, R ^b   Dua, G ^a   Van Den Weyngaert, D ^a   Mahler, Ch ^a  

^a MIDDELHEIM HOSPITAL   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER SURGERY; CASE REPORT; DROWSINESS; HUMAN; HYDROCEPHALUS; HYPOPHYSIS ADENOMA; MALE; SURGICAL APPROACH; SURGICAL TECHNIQUE; VISUAL DISORDER;

EID: 0031969179     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1080/17843286.1998.11754141     Document Type: Article

References (32)

1. Tindall T, Barrow DL, Martin JB. Nonfunctional pituitary adenomas. In: Berger K, Gilfillan SL, eds. Disorders of the pituitary. Toronto: CV Mosby Company. 1986; 281-99.
2. Decker RE, Chalif DJ. Progressive coma after transsphenoidal decompression of a pituitary adenoma with marked suprasellar extension. Neurosurgery. 1991; 28: 154-8.
3. Shenkin HA, Crowley JN. Hydrocephalus complicating pituitary adenoma. J Neurol Neurosurg Psychiatry. 1973; 136: 1063-8.
4. Aleksic SN, George AE. Dementia and low-pressure hydrocephalus in a patient with pituitary adenoma. J Neurol Sci. 1973; 19: 341-9.
5. Perani D, Colombo N, Scotti G, Tonon C. Rapid size reduction of a giant prolactinoma following medical treatment. J Comput Assist Tomogr. 1984; 8: 131-3.
6. Hardy J, Vezina JL. Transsphenoidal neurosurgery of intracranial neoplasms. In: Green RA, ed. Advances in neurology. New York: Raven Press. 1976; 261-74.
7. Zimmerman EA. Tumors of the pituitary gland. In: Rowland LP, ed. Merritt's textbook of neurology. Philadelphia: Lea and Febiger. 1989; 318-26.
8. Snyder PJ. Extensive personal experience: gonadotroph adenomas. J Clin Endocrinol Metab. 1995; 180: 1059-61.
9. Wilson CB, Dempsey LC. Transsphenoidal microsurgical removal of 250 pituitary adenomas. J Neurosurg. 1978; 148: 13-22.
10. Mohr G, Hardy J, Comtois R, Beauregard H. Surgical management of giant pituitary adenomas. Can J Neurol Sci. 1990; 117: 62-6.
11. Snyder PJ. Clinically nonfunctioning pituitary adenomas. Endocrinol Metab Clin North Am. 1993; 22: 163-75.
12. Snyder N. Gonadotroph cell pituitary adenomas. Endocrinol Metab Clin. 1987; 16: 755-64.
13. Nobels FRE, Kwekkeboom DJ, Coopmans W et al. A comparison between the diagnostic value of gonadotropins, α-subunit and chromogranin-A and their response to thyrotropin releasing hormone in clinically nonfunctioning, α-subunit-secreting and gonadotroph pituitary adenomas. J Clin Endocrinol Metab. 1993; 77: 784-9.
14. Kwekkeboom DJ, de Jong FH, Lamberts SW. Gonadotropin release by clinically nonfunctioning and gonadotroph pituitary adenomas in vivo and in vitro: relation to sex and effects of thyrotropin-releasing hormone, gonadotropin-releasing hormone and bromocriptine. J Clin Endocrinol Metab. 1989; 68: 1128-35.
15. Pothe H. Zur Diagnostik und Therapie der Foramen-Monroi-Verschlüsse. Neurochirurgia. 1986; 29: 105-8.
16. Van Alphen HA. Microsurgical fronto-temporal approach to pituitary adenomas with extrasellar extension. Clin Neurol Neurosurg. 1975; 78: 246-56.
17. Black PM, Zervas NT, Candia G. Management of large pituitary adenomas by transsphenoidal surgery. Surg Neurol. 1988; 29: 443-7.
18. Trautmann JC, Laws ER. Visual status after transsphenoidal surgery at the Mayo Clinic, 1971-1982. Am J Ophtalmol. 1983; 96: 200-8.
19. Moss WT. The pituitary gland. In: Moss WT, Cox JD, eds. Moss' radiation oncology: rationale, technique, results. St. Louis: Mosby - Year Book, Inc. 1994; 782-92.
20. Grigsby PW. Pituitary. In. Perez CA, Brady LW, eds. Principles and practice of radiation oncology. Philadelphia. JB Lippincott Company. 1992; 568-82.
21. Movsas B, Movsas TZ, Steinberg SM, Okunieff P. Long-term visual changes following pituitary irradiation. Int J Radiat Oncol Biol Phys. 1995; 33: 599-605.
22. Grabenbauer GG, Fletkau R, Buchfielder M et al. Hormoninaktive Hypophysenadenome: Resultate und Spätfolgen nach Operation und Radiotherapie. Strahlenther Onkol. 1996; 172: 193-7.
23. Flickinger X, Nelson PB, Martinez AJ, Deutsch M, Taylor F. Radiotherapy of nonfunctional adenomas of the pituitary gland: results with long-term follow-up. Cancer. 1989; 63: 2409-14.
24. Fisher BJ, Gaspar LE, Noone B. Giant pituitary adenomas: role of radiotherapy. Int J Radiat Oncol Biol Phys. 1993; 25: 677-81.
25. Bevan JS, Webster J, Burke CW Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev. 1992; 13: 220-40.
26. Johnston DG, Hall K, McGregor A, Ross WM, Kendall-Taylor P, Hall R. Bromocriptine for "nonfunctioning" pituitary tumors. Am J Med. 1981; 71: 1059-61.
27. Vance ML, Ridgway EC, Thorner MO. Follicle stimulating hormone- and alpha-subunit-secreting pituitary tumor treated with bromocriptine. J Clin Endocrinol Metab. 1985; 61: 580-4.
28. Abs R, Parizel PM, Beckers A. Acute effects of Parlodel-LAR and response to long-term tratment with bromocriptine in a patient with a follicle stimulating hormone-secreting pituitary adenoina. J Endocrinol Invest. 1991; 14: 135-8.
29. Kwekkeboom DJ, Lamberts SWJ. Long-term treatment with the dopamine agonist CV 205-502 of patients with a clinically non-functioning, gonadotroph or α-subunit secreting pituitary adenoma. Clin Endocrinol. 1992; 36: 171-6.
30. Paoletti AM, Depau GF, Mais V, Guerriero S, Ajossa S, Melis GB. Effectiveness of cabergoline in reducing follicle-stimulating hormone and prolactin hypersecretion from pituitary macroadenoma in an infertile woman. Fertil Steril. 1994; 62: 882-5.
31. Persiani S, Sassolas G, Piscitelli G et al. Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers. J Pharm Sci. 1994; 83: 1421-4.
32. Andreotti AC, Pianezzola E, Persiani S, Pacciarini MA, Strolin Benedetti M, Pontiroll AE. Pharmacokinetics, pharmacodynamics and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0 and 1.5 milligrams) in healthy male volunteers. J Clin Endocrinol Metab. 1995; 80: 841-5